5-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation Insights From a Patient-Level Pooled Analysis of 4 Randomized Trials Comparing Sirolimus-Eluting Stents With Bare-Metal Stents by Caixeta, Adriano et al.
S
c
i
F
F
H
d
M
m
a
f
(
Journal of the American College of Cardiology Vol. 54, No. 10, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
PCLINICAL RESEARCH Interventional Cardiology
5-Year Clinical Outcomes After
Sirolimus-Eluting Stent Implantation
Insights From a Patient-Level Pooled Analysis of 4 Randomized
Trials Comparing Sirolimus-Eluting Stents With Bare-Metal Stents
Adriano Caixeta, MD, PHD,* Martin B. Leon, MD,* Alexandra J. Lansky, MD,*
Eugenia Nikolsky, MD, PHD,* Jiro Aoki, MD, PHD,* Jeffrey W. Moses, MD,* Joachim Schofer, MD,†
Marie-Claude Morice, MD,‡ Erick Schampaert, MD,§ Ajay J. Kirtane, MD, SM,*
Jeffrey J. Popma, MD, Helen Parise, DSC,* Martin Fahy, MSC,* Roxana Mehran, MD*
New York, New York; Hamburg, Germany; Massy, France; Montréal, Quebec, Canada;
and Boston, Massachusetts
Objectives Five-year clinical follow-up has been scheduled per protocol by the 4 Cypher (Cordis/Johnson & Johnson, Warren,
New Jersey) sirolimus-eluting stent (SES) versus bare-metal stent (BMS) randomized trials.
Background A delayed arterial healing response after drug-eluting stent implantation has raised concerns about the long-
term safety of drug-eluting stents.
Methods In a pooled analysis of 4 randomized trials, 1,748 patients were assigned to receive either an SES (n  878) or
BMS (n  870).
Results At 5 years, there was no significant difference in the rate of death, myocardial infarction (MI), or the composite
of death/MI between the 2 groups (15.1% in the SES group vs. 13.6% in the BMS group; p  0.36). The 5-year
incidence of stent thrombosis by the Academic Research Consortium definition did not differ between SES and
BMS (definite/probable stent thrombosis, 2.1% vs. 2.0%; p  0.99). The incidence of very late stent thrombosis
was also similar between the SES and BMS groups (1.4% vs. 0.7%; p  0.22). The annualized rates of definite/
probable stent thrombosis after 1 year were 0.4% for SES and 0.2% for BMS. The 5-year incidence of target ves-
sel revascularization was significantly lower in the SES group (15.2% vs. 30.1%; p  0.0001).
Conclusions In this patient-level pooled analysis, overall use of SES compared with BMS demonstrated persistent superior
efficacy at 5 years in terms of a reduction in target vessel revascularization, without an increase in rates of
death, MI, or stent thrombosis. (The Initial Double-Blind Drug-Eluting Stent vs Bare-Metal Stent Study,
NCT00233805; The Study of the BX Velocity Stent in the Treatment of De Novo Artery Lesions, NCT00381420;
Study of Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in Treatment of de Novo Native Coronary Ar-
tery Lesions [SIRIUS], NCT00232765; The Study of the BX VELOCITY Stent In Patients With De Novo Coronary
Artery Lesions, NCT00235144) (J Am Coll Cardiol 2009;54:894–902) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.077a
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Mirolimus-eluting stents (SES) dramatically reduce the in-
idence of restenosis and rates of target lesion revascular-
zation (TLR) (1). Soon after approval, SES were enthusi-
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honoraria$10,000) with Cordis Canada/Johnson & Johnson and Boston Scientific, astically adopted even beyond the on-label, U.S. Food and
rug Administration-approved indications. However, the
heoretical thrombogenicity of drug-eluting stents (DES)
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September 1, 2009:894–902 5-Year Outcomes After SES Implantationnd the delayed arterial healing response seen with DES use
aised concerns that these devices might be associated with
n increase in the incidence of very late stent thrombosis
2,3).
Although 4-year clinical outcomes in a pooled analysis
f data from the 4 double-blind SES versus bare-metal
tent (BMS) trials have been published recently (4), the
ES manufacturer was required by the U.S. Food and
rug Administration to follow patients for 5 years (5).
o further address the issue of long-term safety and
fficacy of SES, we investigated 5-year clinical outcomes
n a pooled analysis of the 4 SES versus BMS randomized
rials.
ethods
atient population and study procedure. We performed a
atient-level pooled analysis of the 4 multicenter, double-
linded, randomized SES versus BMS trials, including the
AVEL (Randomized Study With the Sirolimus-Coated
x Velocity Balloon-Expandable Stent in the Treatment of
atients With De Novo Native Coronary Artery Lesions),
IRIUS (Sirolimus-Eluting Stent in De Novo Native Cor-
nary Lesions), E-SIRIUS (European–SIRIUS), and
-SIRIUS (Canadian–SIRIUS) trials, in which patients
ith single de novo lesions were treated with either a
Baseline Clinical and Procedural CharacteristicsTable 1 Baseline Clinical and Procedural Ch
Age (yrs) 61
Male sex 7
Hypertension 6
Hyperlipidemia 7
Current smoking 2
Diabetes mellitus 2
Prior myocardial infarction 3
Prior percutaneous revascularization 2
Prior coronary artery bypass graft
Multivessel disease 3
Clinical presentation
Stable exertional angina 2
Worsening exertional angina 3
Rest angina 2
Ejection fraction (%) 56
Location of target lesion
Left anterior descending artery 4
Left circumflex artery 2
Right coronary artery 2
Modified ACC/AHA lesion classification
A
B1 3
B2 3
C 2
Pre-reference vessel diameter, mm 2
Total implanted stent length, mm 22
Number of total implanted stents 1
Glycoprotein IIb/IIIa inhibitors during procedure 4ACC  American College of Cardiology; AHA  American Heart Association;ypher SES or an uncoated Bx
elocity BMS of identical design
both Cordis/Johnson & John-
on, Warren, New Jersey). The
rotocol and principal results of
ach trial have been published
lsewhere (1,6–8).
efinitions and clinical end
oints. The primary safety end
oint of this analysis was death
r myocardial infarction (MI).
he secondary safety end point
as stent thrombosis using the
cademic Research Consor-
ium (ARC) definition up to 5
ears (9). The primary efficacy end point was target vessel
evascularization (TVR) up to 5 years. Follow-up infor-
ation was collected by the investigating sites, including
elephone contact at 1 year and annually for 5 years
hereafter. Five-year follow-up was completed in 87.1%
f patients. To be included in the analysis, patients must
ave had at least 1,800 days of follow-up.
We pre-specified that we would compare the clinical
utcomes between the SES and BMS groups in patients
ith diabetes, because the mortality rate was signifi-
teristics
ES BMS p Value
1.12 61.91 10.67 0.91
629/878) 71.5% (622/870) 0.96
557/873) 63.3% (548/866) 0.84
613/866) 71.8% (617/859) 0.67
183/862) 24.5% (210/858) 0.12
195/878) 26.8% (233/868) 0.03
287/865) 35.7% (308/862) 0.27
201/878) 21.2% (184/869) 0.39
66/878) 7.4% (64/870) 0.93
338/876) 38.8% (337/868) 0.92
202/875) 25.0% (217/869) 0.37
277/757) 33.3% (250/751) 0.19
166/757) 21.8% (164/751) 1.00
1.02 (726) 57.34 10.99 (717) 0.55
408/875) 46.7% (407/872) 1.00
181/875) 20.8% (181/872) 1.00
254/875) 29.1% (254/872) 1.00
61/875) 7.0% (61/871) 1.00
297/875) 36.4% (317/871) 0.29
320/875) 38.1% (332/871) 0.52
197/875) 18.5% (161/871) 0.04
.45 (871) 2.72 0.48 (868) 0.98
.03 (877) 22.45 8.13 (869) 0.31
.69 (878) 1.39 0.61 (870) 0.38
388/878) 43.4% (377/869) 0.74
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
MI  myocardial infarction
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
TVR  target vessel
revascularizationarac
S
.85 1
1.6% (
3.8% (
0.8% (
1.2% (
2.2% (
3.2% (
2.9% (
7.5% (
8.6% (
3.1% (
6.6% (
1.9% (
.99 1
6.6% (
0.7% (
9.0% (
7.0% (
3.9% (
6.6% (
2.5% (
.72 0
.87 9
.42 0
4.2% (BMS  bare-metal stent(s); SES  sirolimus-eluting stent(s).
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5-Year Outcomes After SES Implantation September 1, 2009:894–902antly higher in the SES group at 4 years in the published
eport (4).
Definitions of major adverse cardiac events were consis-
ent across the trials (1,6–8). Members of the independent
linical Events Committee retrospectively readjudicated all
linical and angiographic data based on the ARC definition
f stent thrombosis (9).
tatistical analysis. Patient-level data were pooled from
he 4 randomized trials comparing SES and BMS.
nteractions between trial and stent on 5-year death, MI,
LR, TVR, protocol thrombosis, and ARC-defined
hrombosis were not statistically significant, justifying
ooling of the 4 studies. Binary variables are summarized
s counts and percentages and compared using chi-square
ests or the Fisher exact test where appropriate. Contin-
ous variables are summarized as means and standard
eviations and compared using t tests. Five-year out-
omes are summarized as Kaplan-Meier estimates and
ompared using log-rank tests and hazard ratios. Kaplan-
eier event curves are presented and compared using
og-rank tests. To assess events occurring between years 4
nd 5, a landmark analysis was performed. Cox propor-
Cumulative Clinical Outcomes Up to 5 Years anTable 2 Cumulative Clinical Outcomes Up to
SES
0–5 yrs
Death 8.9% (76)
Cardiac death 4.4% (37)
Noncardiac death 4.7% (39)
MI 7.9% (67)
Q-wave 2.5% (21)
Non–Q-wave 5.7% (48)
TLR 9.6% (80)
TVR 15.2% (127)
Death/MI 15.1% (130)
Cardiac death/MI 11.1% (94)
Death/Q-wave MI 10.7% (91)
Cardiac death/Q-wave MI 6.2% (52)
Death/MI/TLR 21.5% (185)
Death/MI/TVR 26.2% (225)
1 yr
Death 7.7% (65)
Cardiac death 4.0% (33)
Noncardiac death 3.9% (32)
MI 4.2% (34)
Q-wave 1.3% (10)
Non–Q-wave 3.2% (26)
TLR 5.3% (43)
TVR 9.6% (78)
Death/MI 11.0% (92)
Cardiac death/MI 7.5% (62)
Death/Q-wave MI 8.6% (72)
Cardiac death/Q-wave MI 4.9% (40)
Death/MI/TLR 14.4% (121)
Death/MI/TVR 18.1% (152)CI  confidence interval; MI  myocardial infarction; TLR  target lesi
abbreviations as in Table 1.ional hazards models using stepwise selection were used
o determine multivariate predictors of clinical events. All
tatistical tests were 2-tailed. A p value 0.05 denoted
ignificance.
esults
aseline and procedural characteristics. Between August
000 and April 2002, 1,748 patients at 115 international
enters were assigned to either SES (n  878) or BMS (n 
70). The 2 groups were well matched for all baseline and
rocedural characteristics except for a lower prevalence of
iabetes in patients randomized to SES and a lower rate of type
lesions in patients randomized to BMS (Table 1).
linical outcomes up to 5 years. The 5-year rates of
ll-cause death, cardiac death, and MI were similar between
he 2 groups (Table 2). There were no significant differences
n the composite end point of death or MI at 5 years and
rom 1 to 5 years between the 2 groups. The 5-year
umulative incidence of TVR was nearly doubled in patients
andomized to BMS. The striking difference in the TVR
ween 1 and 5 Yearsears and Between 1 and 5 Years
MS Hazard Ratio (95% CI) p Value
(69) 1.10 (0.79–1.52) 0.57
(32) 1.16 (0.72–1.85) 0.55
(37) 1.05 (0.67–1.65) 0.83
(58) 1.15 (0.81–1.63) 0.44
(13) 1.62 (0.81–3.23) 0.17
(46) 1.03 (0.69–1.55) 0.87
(207) 0.34 (0.27–0.44) 0.0001
(252) 0.44 (0.36–0.55) 0.0001
(115) 1.12 (0.88–1.45) 0.36
(83) 1.13 (0.84–1.51) 0.43
(79) 1.15 (0.85–1.56) 0.35
(42) 1.24 (0.83–1.86) 0.29
(289) 0.56 (0.47–0.68) 0.0001
(327) 0.60 (0.50–0.71) 0.0001
(62) 1.05 (0.74–1.48) 0.79
(28) 1.18 (0.71–1.95) 0.52
(34) 0.94 (0.58–1.52) 0.80
(22) 1.55 (0.90–2.64) 0.11
(7) 1.43 (0.54–3.76) 0.46
(16) 1.62 (0.87–3.02) 0.12
(30) 1.44 (0.90–2.29) 0.13
(64) 1.22 (0.87–1.69) 0.24
(79) 1.17 (0.86–1.57) 0.32
(46) 1.35 (0.92–1.98) 0.12
(67) 1.08 (0.77–1.50) 0.67
(33) 1.21 (0.77–1.93) 0.40
(106) 1.14 (0.88–1.48) 0.33
(137) 1.10 (0.88–1.39) 0.40d Bet5 Y
B
8.2%
3.9%
4.5%
6.8%
1.6%
5.4%
24.7%
30.1%
13.6%
9.8%
9.4%
5.0%
34.1%
38.5%
7.5%
3.4%
4.2%
2.7%
0.9%
2.0%
4.1%
8.3%
9.5%
5.6%
8.1%
4.0%
13.1%
16.8%on revascularization; TVR  target vessel revascularization; other
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September 1, 2009:894–902 5-Year Outcomes After SES ImplantationFigure 1 Kaplan-Meier Event Curves for Patients Treated With SES or BMS
Five-year cumulative event curves for (A) death, (B) death or myocardial infarction
(MI), and (C) target vessel revascularization (TVR). BMS  bare-metal stent(s); SES  sirolimus-eluting stent(s).Incidence of ST According to Academic Research Consortium DefinitionTable 3 Incidence of ST According to Academic Research Consortium Definition
Definition SES BMS Hazard Ratio (95% CI) p Value
All (0–5 yrs)
Definite ST 1.6% (13) 1.0% (8) 1.62 (0.67–3.91) 0.23
Definite  probable ST 2.1% (17) 2.0% (17) 0.99 (0.51–1.95) 0.99
Any (definite  probable  possible) ST 4.6% (38) 4.4% (37) 1.02 (0–65–1.61) 0.70
Early (0–30 days)
Definite ST 0.3% (3) 0.0% (0) NA 0.08
Definite  probable ST 0.5% (4) 0.3% (3) 1.33 (0.30–5.93) 0.71
Any (definite  probable  possible) ST 0.5% (4) 0.3% (3) 1.33 (0.30–5.93) 0.71
Late (30 days–1 yr)
Definite ST 0.1% (1) 0.5% (4) 0.25 (0.03–2.22) 0.18
Definite  probable ST 0.2% (2) 0.9% (8) 0.25 (0.05–1.16) 0.05
Any (definite  probable  possible) ST 0.3% (3) 1.3% (11) 0.27 (0.08–0.97) 0.03
Very late (1–5 yrs)
Definite ST 1.1% (9) 0.5% (4) 2.25 (0.69–7.30) 0.16
Definite  probable ST 1.4% (11) 0.7% (6) 1.83 (0.68–4.95) 0.22
Any (definite  probable  possible) ST 3.8% (31) 2.8% (23) 1.35 (0.79–2.31) 0.28NA  not applicable; ST  stent thrombosis; other abbreviations as in Tables 1 and 2.
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5-Year Outcomes After SES Implantation September 1, 2009:894–902ates peaked at approximately 1 year and then remained
hrough 5 years (Fig. 1).
The incidence of any stent thrombosis did not differ
etween the 2 groups at 5 years (Table 3, Fig. 2). The rates
f very late definite stent thrombosis (1.1% in the SES
roup vs. 0.5% in the BMS group; p  0.16) and very late
efinite or probable stent thrombosis (1.4% in the SES
roup vs. 0.7% in the BMS group; p  0.22) were also
imilar between the 2 groups.
Late definite or probable stent thrombosis was more
requent in the BMS group during the first year (0.2% in
he SES group vs. 0.9% in the BMS group; p  0.05),
hereas very late definite or probable stent thrombosis
ended to be more frequent in the SES group (1.4% vs.
.7%; p  0.22) (Table 3). The annual definite or
robable stent thrombosis rate from 1 to 5 years was low
n both groups and did not differ significantly between
ES and BMS (0.4% vs. 0.2% per year) (Table 4). The
nnualized rates of TLR, TVR, and nontarget lesion
VR (remote TVR) after 1 year were similar for SES and
MS. In the landmark analysis, there were no significant
Figure 2 Kaplan-Meier Curves for Patients With Stent Thrombo
Five-year cumulative event curves for (A) any stent thrombosis, (B) definite stent t
definite and probable stent thrombosis. ARC  Academic Research Consortium; oifferences in rates of the clinical end points, including ctent thrombosis between years 4 and 5 in patients
reated with SES versus BMS (Fig. 3).
linical outcomes in patients with diabetes. At 5 years,
iabetic patients treated with SES versus BMS had signif-
cantly higher rates of mortality (15.9% vs. 9.0%; p  0.03)
nd Q-wave MI (3.3% vs. 0.4%; p  0.03) and had no
ignificant differences in rates of definite, definite or prob-
ble, or any stent thrombosis either at 5 years or from 1 to
years (Table 5, Fig. 4). At 5 years, the use of SES
ompared with BMS reduced the rate of TVR from 37.1%
o 17.7% (p  0.0001).
ultivariable analysis. Independent predictors of car-
iac death or MI for the entire population were smoking
hazard ratio [HR]: 1.85; 95% confidence interval [CI]:
.34 to 2.57; p  0.0002), congestive heart failure (HR:
.79; 95% CI: 1.13 to 2.83; p  0.01), diabetes (HR:
.37; 95% CI: 1.01 to 1.86; p  0.041), prior MI (HR:
.49; 95% CI: 1.12 to 1.97; p  0.006), older age (HR: 1.05;
5% CI: 1.03 to 1.06; p 0.0001), and total number of stents
mplanted (HR: 1.02; 95% CI: 1.01 to 1.03; p 0.001). In the
iabetes subset, predictors of cardiac death or MI included
s Defined by the ARC
osis, and (C)
breviations as in Figure 1.sis a
hromb
ther abongestive heart failure (HR: 2.33; 95% CI: 1.27 to 4.29; p 
AAbbreviations as in Tables 1 to 3.
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September 1, 2009:894–902 5-Year Outcomes After SES ImplantationFigure 3 Kaplan-Meier Event Curves With Landmark Analysis From 4- to 5-Year Follow-Up
Landmark analyses of (A) cardiac death, (B) cardiac death or MI, and (C) definite and probable stent thrombosis. Abbreviations as in Figures 1 and 2.nnualized Hazard Ratio per 100 Patient-YearsTable 4 Annualized Hazard Ratio per 100 Patient-Years
Year 1 Annual Hazard Rate per
100 Patient-Years
Years 2 to 5 Annual Hazard Rate per
100 Patient-Years
SES BMS p Value SES BMS p Value
Death 1.3% (11) 0.8% (7) 0.35 1.9% 1.9% 0.79
Cardiac death 0.5% (4) 0.5% (4) 0.99 1% 0.9% 0.52
Noncardiac death 0.8% (7) 0.3% (3) 0.21 1% 1.1% 0.80
MI 3.8% (33) 4.1% (36) 0.70 1.1% 0.7% 0.11
Q-wave 1.3% (11) 0.7% (6) 0.23 0.3% 0.2% 0.46
Non–Q-wave 2.5% (22) 3.5% (30) 0.25 0.8% 0.5% 0.12
TLR 4.3% (37) 20.5% (177) 0.0001 1.3% 1% 0.13
TVR 9.5% (82) 25.3% (218) 0.0001 2.4% 2.1% 0.24
Remote TVR (non-TLR) 2.6% (23) 5.0% (43) 0.011 1.4% 1.3% 0.67
Definite ST 0.5% (4) 0.5% (4) 0.99 0.3% 0.1% 0.16
Definite  probable ST 0.7% (6) 1.3% (11) 0.22 0.4% 0.2% 0.22
Any ST (definite  probable  possible) 0.8% (7) 1.6% (14) 0.12 1% 0.7% 0.28
Death/MI 4.9% (43) 4.6% (40) 0.76 2.8% 2.4% 0.31
Death/Q-wave MI 1.3% (11) 0.8% (7) 0.35 2.2% 2% 0.67
Death/MI/TVR 13.0% (114) 27.9% (242) 0.0001 4.5% 4.2% 0.40
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5-Year Outcomes After SES Implantation September 1, 2009:894–902.006), smoking (HR: 2.06; 95% CI: 1.11 to 3.81; p  0.02),
nd older age (HR: 1.05; 95% CI: 1.02 to 1.08; p  0.0005).
iscussion
he main findings of this analysis comparing 5-year
linical outcomes in patients treated with either SES or
MS for on-label indications were as follows: 1) the
ncidences of the composite of death or MI as well as
RC-defined stent thrombosis were similar up to 5 years
nd from 1 to 5 years between the 2 groups; 2) a
ignificant difference in the incidence of TVR favoring
he SES group versus the BMS group within the first year
as maintained up to 5 years; and 3) in diabetic patients,
he rates of mortality and the composite of death or
-wave MI were significantly higher in patients receiving
ES versus BMS.
ong-term safety of SES. Due to safety concerns (5),
-year follow-up was required from the manufacturer for
linical Outcomes in Diabetic PatientsTable 5 Clinical Outcomes in Diabetic Patients
SES
0–5 yrs
Death 15.9% (30)
Cardiac death 10.5% (19)
Noncardiac death 6.0% (11)
MI 8.3% (15)
Q-wave 3.3% (6)
Non–Q-wave 5.5% (10)
TLR 11.9% (22)
TVR 17.7% (33)
Death/MI 21.0% (40)
Cardiac death/MI 16.3% (30)
Death/Q-wave MI 17.4% (33)
Death/MI/TLR 29.3% (56)
Death/MI/TVR 33.5% (64)
Definite ST 1.7% (3)
Definite  probable ST 2.4% (4)
Any ST (definite  probable  possible) 8.4% (15)
1 yr
Death 14.1% (26)
Cardiac death 10.0% (18)
Noncardiac death 4.5% (8)
MI 5.2% (9)
Q-wave 1.8% (3)
Non–Q-wave 4.0% (7)
TLR 4.6% (8)
TVR 9.4% (17)
Death/MI 17.3% (32)
Death/Q-wave MI 14.6% (27)
Death/MI/TLR 19.9% (37)
Death/MI/TVR 23.1% (43)
Definite ST 1.2% (2)
Definite  probable ST 1.9% (3)
Any ST (definite  probable  possible) 7.9% (14)
A  not applicable; other abbreviations as in Tables 1 to 3.atients enrolled in randomized DES versus BMS trials. in 1 community-based registry, very late stent thrombosis
ccurred at a constant rate of 0.6% per year up to 3 years after
ES implantation (2). Higher rates of very late stent throm-
osis with SES rather than BMS (1.4% vs. 0%; p 0.02) have
een also shown at 4-year follow-up in another large-scale
egistry (10). However, despite concern initially raised about
ES safety based on 3-year outcomes from the large Swedish
egistry, repeat analysis performed at later follow-up (at 4 years)
emonstrated no differences in hard clinical end points be-
ween patients treated with DES or BMS (11). These latter
esults are consistent with the present study, in which rates of
eath and MI were similar for SES- and BMS-treated patients
uring 1 to 5 years of follow-up. Even though the annual
ncidence of definite or probable stent thrombosis after the first
ear was 2-fold higher in the SES group compared with the
MS group (0.4% vs. 0.2%), the difference was not statistically
ignificant. Still, the lack of an observed difference between
ard clinical end points, including stent thrombosis, for SES-
nd BMS-treated patients in this study may be due to
BMS Hazard Ratio (95% CI) p Value
9.0% (20) 1.88 (1.07–3.32) 0.03
5.0% (11) 2.17 (1.03–4.56) 0.04
4.2% (9) 1.53 (0.64–3.70) 0.34
9.2% (21) 0.85 (0.44–1.64) 0.62
0.4% (1) 7.41 (0.89–61.54) 0.03
8.8% (20) 0.59 (0.28–1.26) 0.16
31.9% (73) 0.32 (0.20–0.52) 0.0001
37.1% (84) 0.41 (0.28–0.62) 0.0001
16.4% (37) 1.30 (0.83–2.03) 0.25
12.8% (29) 1.24 (0.74–2.06) 0.41
9.0% (20) 2.10 (1.20–3.65) 0.008
42.2% (97) 0.59 (0.42–0.82) 0.001
46.2% (106) 0.62 (0.45–0.84) 0.002
0.9% (2) 1.87 (0.31–11.16) 0.49
2.7% (6) 0.82 (0.23–2.89) 0.75
5.8% (13) 1.43 (0.68–3.00) 0.35
7.8% (17) 1.93 (1.05–3.56) 0.03
4.2% (9) 2.52 (1.13–5.62) 0.02
3.8% (8) 1.27 (0.48–3.38) 0.63
3.2% (7) 1.60 (0.59–4.29) 0.35
0.0% (0) NA 0.05
3.2% (7) 1.23 (0.43–3.52) 0.69
5.5% (12) 0.82 (0.34–2.02) 0.67
10.1% (22) 0.96 (0.51–1.81) 0.91
11.0% (24) 1.67 (0.98–2.84) 0.05
7.8% (17) 2.02 (1.10–3.70) 0.02
15.9% (35) 1.30 (0.82–2.06) 0.26
19.5% (43) 1.24 (0.81–1.89) 0.32
0.5% (1) 2.55 (0.23–28.10) 0.43
0.9% (2) 1.90 (0.32–11.38) 0.47
3.3% (7) 2.52 (1.02–6.25) 0.04nadequate statistical power.
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September 1, 2009:894–902 5-Year Outcomes After SES ImplantationThe current study provides information on the longest
5-year) follow-up, including an update on clinical events
ccurring between 4 and 5 years. After the completion of
-year follow-up (4), patients treated with SES versus BMS
ad 8 versus 9 additional cases of cardiac death, 3 versus 2
ases of Q-wave MI, and 4 versus 2 cases of very late definite
r probable stent thrombosis, respectively.
linical outcomes in diabetic patients. Mortality in di-
betic patients was significantly higher in the SES group
han the BMS group, mainly due to a higher rate of
ardiac death beyond 1 year. Among 19 diabetic patients
ho experienced cardiac death in the SES group, 11
57.9%) died of unknown causes; these cases were adju-
icated as cardiac death and possible stent thrombosis.
owever, it is not certain that this higher mortality is in
act related to late stent thrombosis. Furthermore, the
mall number of diabetic patients in the current study
akes it underpowered to detect differences between the
groups for rare events such as death and stent throm-
Figure 4 Kaplan-Meier Event Curves for Patients With and With
Five-year cumulative event curves for (A) death and (B) death or MI for patients w
cumulative event curves for (C) death and (D) death or MI for patients without diaosis. In addition, the surprisingly low event rates in the lMS group beyond 1 year may have biased the outcomes
n favor of BMS. Therefore, the difference in SES versus
MS mortality seen at 5 years in patients with diabetes
ay be due to chance alone. Larger, more recent studies
rovide evidence of superior outcomes (12,13), including
ower mortality and fewer MIs (12), in diabetic patients
reated with DES compared with BMS.
ong-term efficacy of SES. In this pooled analysis, TVR
t 5-year follow-up was reduced nearly 2-fold in the SES
ersus BMS group, mainly due to remarkably lower rates of
LR during the first year. The highly significant differences
n rates of TLR and TVR between patients randomized to
ES versus BMS persisted from 1 to 5 years. Thus, it is
nlikely that the use of SES is associated with a late
atch-up phenomenon.
tudy limitations. The results of this analysis are
ypothesis-generating. Information about patient adher-
nce to antiplatelet therapy at follow-up was not collected.
nsufficient antiplatelet therapy as a significant predictor of
iabetes
betes, and
Abbreviations as in Figure 1.out D
ith dia
betes.ate stent thrombosis was not a concern in 2002, when
p
r
a
r
b
C
I
d
r
o
A
T
R
F
1
R
1
1
1
1
K
902 Caixeta et al. JACC Vol. 54, No. 10, 2009
5-Year Outcomes After SES Implantation September 1, 2009:894–902atient enrollment in the trials was completed. Therefore, a
elationship between duration of dual antiplatelet therapy
nd stent thrombosis cannot be established. Finally, the
esults of this study cannot be generalized for the use of SES
eyond the approved (off-label) indications.
onclusions
n this pooled analysis, the use of SES compared with BMS
emonstrated persistent superior efficacy in terms of a
eduction in TVR without an increase in rates of death, MI,
r stent thrombosis for up to 5 years and from 1 to 5 years.
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